Curidium Medica plc, (LSE: CUR) has discovered four unique and statistically significantly different subgroups of schizophrenia/bipolar disorder patients based on their gene expression profiles. Using its proprietary Homomatrix(R), Curidium analyzed the gene expression profiles of post-mortem brains of 64 schizophrenic/bipolar disorder patients and matched controls.

These expression profiles were the result of a genome-wide screening of more than 22,000 gene probes using the Affymetrix Genechip(TM) technology (conducted by the Harvard Brain Tissue Resource Centre).

Each patient/control was a member of only one of the four subgroups and each subgroup was associated with a unique and finite number of genes. Furthermore, the differences between the subgroups were statistically significant (p<0.001). The genes identified in each subgroup include known and novel drug targets.

Curidium Medica is in the process of analyzing a second set of gene expression data from the post-mortem brains of a separate and different group of patients and controls to confirm these findings.

About Homomatrix(R)
Homomatrix(R) is a fully automated analysis tool that uses proprietary pattern recognition tools and sequences of mathematical algorithms together with state-of-the-art statistical methods to objectively analyze large sets of gene expression and biological data from heterogeneous populations.

These analyses can potentially lead to the development of diagnostics that identify treatment-responsive patients and/or patient subgroups, signaling pathways as well as drug targets. It is anticipated that Homomatrix(R) could be of significant value in the drug development arena where the “most likely to respond” patients could be pre-selected to clinical trials.

About Curidium
Curidium is a company focused on identifying targeted medicines to treat patients more effectively. Through the application of its proprietary technology, Homomatrix(R), Curidium analyses biological data (mRNA/protein data) from patients suffering from complex or multi-factorial diseases.

Patient populations with complex disorders are known to be heterogeneous and only certain subgroups of patients respond to a specific treatment. Curidium believes that Homomatrix(R) will ultimately allow for the development of the right drug for the right patient. The Company files patents around the genes and drug targets that are associated with the specific subgroups of patients.

Further information on Curidium can be found at the Company’s website: www.curidium.com.

Related Health News:

1. Lexicon Reports on Anti-Angiogenesis Target Discoveries Lexicon Genetics Incorporated (NASDAQ:LEXG) today presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization. These results were...
2. Kryptiq Unveils Tools for Secure Healthcare Communication and Online Patient Services Kryptiq Corporation, the leading provider of workflow and connectivity solutions for healthcare, has released Software Development Kits (SDKs) for its CareCatalyst and Kryptiq Gateway products....
3. Metabolex Shows MBX-102 JNJ-39659100 Reduces Inflammation in Preclinical Models of Diabetes Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced the results from a...
4. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia - Findings from an Otsuka Pharmaceutical Co, Ltd. Sponsored Study Presented at the American Psychiatric Association Annual Meeting - SAN DIEGO, May 23 /PRNewswire/ --...
5. Lipitor Significantly Reduces Risk of Serious Cardiovascular Events An analysis of a large U.S. managed care database showed that patients who took Pfizer's cholesterol-lowering medicine Lipitor(R) (atorvastatin calcium) Tablets had a significant 14...